{
 "id": "chronic-kidney-disease",
 "name": "Chronic Kidney Disease",
 "aliases": [
  "Chronic kidney disease (CKD)"
 ],
 "acronyms": [
  "CKD"
 ],
 "bodySystem": "kidney",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 2
 },
 "funds": [
  {
   "fund": "Chronic Kidney Disease",
   "organization": "Good Days",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page marks the fund as seeking funds for new enrollments (the fund's list item on the page carries the class seeking), so it is not open to applications.",
   "readOn": "2026-11-08",
   "source": "https://mygooddays.org/patients/diseases-covered/"
  },
  {
   "fund": "Chronic kidney disease (CKD)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 4800,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "DAPAGLIFLOZIN",
   "pages": [
    {
     "brand": "Farxiga",
     "url": "https://omnirx.org/negotiated-drugs/farxiga"
    }
   ],
   "labelSentence": "To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2201f90c94-71cb-4a1f-81ff-8004b850529b%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Farxiga Savings (via AstraZeneca)",
     "url": "https://omnirx.org/assistance/farxiga-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": false,
     "note": null,
     "listKind": "Important Program Updates page: product additions and removals only (not the full list)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 183.33,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "EMPAGLIFLOZIN",
   "pages": [
    {
     "brand": "Jardiance",
     "url": "https://omnirx.org/negotiated-drugs/jardiance"
    }
   ],
   "labelSentence": "... to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22334f1b3d-5670-6685-e063-6294a90a7e47%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Jardiance Savings (via Boehringer Ingelheim/Lilly)",
     "url": "https://omnirx.org/assistance/jardiance-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 202.33,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "SEMAGLUTIDE",
   "pages": [
    {
     "brand": "Ozempic",
     "url": "https://omnirx.org/negotiated-drugs/ozempic"
    }
   ],
   "labelSentence": "... to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2242bdd912-2393-44c4-b7e0-47672ca28991%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Ozempic Savings (via NovoCare)",
     "url": "https://omnirx.org/assistance/ozempic-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Novo Nordisk PAP (NovoCare)",
     "url": "https://omnirx.org/assistance/novo-nordisk-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "0.5 mg, 1 mg, or 2 mg",
     "listKind": "Available Products (PAP product list PDF)",
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 274,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Empagliflozin/Metformin HCl",
   "pages": [
    {
     "brand": "Synjardy XR",
     "url": "https://omnirx.org/medicines/synjardy-xr"
    },
    {
     "brand": "Synjardy",
     "url": "https://omnirx.org/medicines/synjardy"
    }
   ],
   "labelSentence": "Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220fdd0255-0055-65f3-b2c0-db8fbb87beae%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Finerenone",
   "pages": [
    {
     "brand": "Kerendia",
     "url": "https://omnirx.org/medicines/kerendia"
    }
   ],
   "labelSentence": "... cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22fc726765-5d5a-4d6e-b037-b847bda9fb7c%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Bayer US Patient Assistance Foundation",
     "url": "https://www.patientassistance.bayer.us/en/about/bayer-products",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Bayer prescription medicines included in the program",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Ferric Citrate",
   "pages": [
    {
     "brand": "Auryxia",
     "url": "https://omnirx.org/medicines/auryxia"
    }
   ],
   "labelSentence": "Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22314bd2e4-2ca5-4e2a-9fea-13373f910f34%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tenapanor HCl",
   "pages": [
    {
     "brand": "Xphozah",
     "url": "https://omnirx.org/medicines/xphozah"
    }
   ],
   "labelSentence": "XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22c57e279c-0f1b-4238-81b7-4e0dc0cc60c5%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}